- Home
- KALV vs CCO Comparison
KALV vs CCO Comparison
Compare KALV & CCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- CCO
- Stock Information
- Founded
- KALV N/A
- CCO 1995
- Country
- KALV United States
- CCO United States
- Employees
- KALV N/A
- CCO N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- CCO Advertising
- Sector
- KALV Health Care
- CCO Consumer Discretionary
- Exchange
- KALV Nasdaq
- CCO Nasdaq
- Market Cap
- KALV 637.9M
- CCO 576.2M
- IPO Year
- KALV N/A
- CCO 2005
- Fundamental
- Price
- KALV $12.34
- CCO $1.05
- Analyst Decision
- KALV Strong Buy
- CCO Hold
- Analyst Count
- KALV 9
- CCO 5
- Target Price
- KALV $26.29
- CCO $1.88
- AVG Volume (30 Days)
- KALV 1.0M
- CCO 2.9M
- Earning Date
- KALV 09-04-2025
- CCO 08-05-2025
- Dividend Yield
- KALV N/A
- CCO N/A
- EPS Growth
- KALV N/A
- CCO N/A
- EPS
- KALV N/A
- CCO 0.04
- Revenue
- KALV N/A
- CCO $1,538,895,000.00
- Revenue This Year
- KALV N/A
- CCO $5.23
- Revenue Next Year
- KALV $192.67
- CCO $3.41
- P/E Ratio
- KALV N/A
- CCO $24.61
- Revenue Growth
- KALV N/A
- CCO 31.61
- 52 Week Low
- KALV $7.30
- CCO $0.81
- 52 Week High
- KALV $16.32
- CCO $1.77
- Technical
- Relative Strength Index (RSI)
- KALV 36.00
- CCO 43.09
- Support Level
- KALV $12.19
- CCO $1.00
- Resistance Level
- KALV $14.35
- CCO $1.25
- Average True Range (ATR)
- KALV 0.61
- CCO 0.07
- MACD
- KALV -0.30
- CCO -0.01
- Stochastic Oscillator
- KALV 5.26
- CCO 25.60
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About CCO Clear Channel Outdoor Holdings Inc.
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.